Klaus Elenius

The research of Elenius lab has focused on the role of growth factor signaling in cancer for over 30 years, including a 3-year period as a post-doctoral fellow in Children’s Hospital, Harvard Medical School, Boston. This has included indentification of novel signaling molecules and development of new predictive and therapeutic tools for the treatment of cancer and inflammatory diseases. The translational research has been complemented by participation in clinical trials. Prof. Elenius has experience in application of technology solutions for medical practice as a co-founder of Abomics Ltd. He has also frequently served as a consultant for and has had research agreements with major pharmaceutical companies developing targeted cancer therapies. Served as a Board Member of Research Council of Finland, Cancer Foundation Finland, Finnish Medical Foundation, and Biocenter Finland. Currently a Distinguished Innovator of the Novo Nordisk Foundation Initiative.